Clinical Trials Logo

Tumor, Solid clinical trials

View clinical trials related to Tumor, Solid.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04840394 Active, not recruiting - Tumor, Solid Clinical Trials

Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Start date: June 22, 2021
Phase: Phase 1
Study type: Interventional

A Phase 1 Open-label Dose Escalation Trial of BDB018 in Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

NCT ID: NCT04528836 Active, not recruiting - Tumor, Solid Clinical Trials

First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors

Start date: November 12, 2020
Phase: Phase 1
Study type: Interventional

A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.

NCT ID: NCT04196530 Active, not recruiting - Tumor, Solid Clinical Trials

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

Start date: November 21, 2019
Phase: Phase 1
Study type: Interventional

A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors

NCT ID: NCT03911557 Active, not recruiting - Tumor, Solid Clinical Trials

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Start date: June 8, 2019
Phase: Phase 2
Study type: Interventional

This study will examine whether patients with relapsed/refractory solid tumors harboring evidence of somatic hypermutation (intermediate versus high tumor mutational burden) will exhibit improvement in disease progression-free survival with dual Tremelimumab and Durvalumab treatment.

NCT ID: NCT03491631 Active, not recruiting - Tumor, Solid Clinical Trials

Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors

Start date: November 20, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial is designed to efficiently identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) for the combination therapy regimen of the IDO1 inhibitor SHR9146 when administered in combination with immune checkpoint PD-1 inhibitor SHR-1210 plus VEGFR inhibitor Apatinib or not in subjects with advanced/metastatic solid tumors. All subjects will receive the same standard SHR-1210 plus Apatinib (only three drugs group)regimen, while SHR9146 in doses increasing from 100 mg twice daily to, potentially, 600 mg twice daily. Once the recommended regimen has been identified, subjects with the selected tumor type will be enrolled into expansion cohorts based upon prior safety and tolerability data.

NCT ID: NCT03486301 Active, not recruiting - Tumor, Solid Clinical Trials

BDB001-101: Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab

Start date: February 15, 2018
Phase: Phase 1
Study type: Interventional

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in combination with Pembrolizumab in Subjects with Advanced Solid Tumors